PolyPid Ltd. (NASDAQ:PYPD – Get Free Report) was the recipient of a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 447,180 shares, a growth of 98.3% from the October 15th total of 225,458 shares. Based on an average trading volume of 128,450 shares, the days-to-cover ratio is presently 3.5 days. Currently, 3.1% of the company’s shares are sold short.
PolyPid Stock Performance
Shares of NASDAQ PYPD traded down $0.14 during midday trading on Friday, hitting $6.26. 193,133 shares of the company traded hands, compared to its average volume of 168,040. PolyPid has a 12-month low of $3.50 and a 12-month high of $7.15. The stock has a 50-day moving average price of $5.37 and a 200 day moving average price of $4.80. The firm has a market cap of $119.44 million, a P/E ratio of -4.64 and a beta of 1.43.
PolyPid (NASDAQ:PYPD – Get Free Report) last issued its quarterly earnings data on Wednesday, November 11th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.91 by ($1.15). The business had revenue of $30.00 million for the quarter, compared to analyst estimates of $30.00 million. As a group, equities analysts expect that PolyPid will post -0.44 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research firms have recently weighed in on PYPD. Oppenheimer assumed coverage on shares of PolyPid in a report on Tuesday, October 27th. They set an “outperform” rating and a $10.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price target on shares of PolyPid in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of PolyPid in a report on Friday, September 18th. Craig Hallum set a $12.00 price objective on PolyPid in a research report on Wednesday, July 22nd. Finally, Wall Street Zen cut PolyPid from a “buy” rating to a “hold” rating in a research note on Saturday. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $11.67.
Check Out Our Latest Research Report on PYPD
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. HighTower Advisors LLC purchased a new position in PolyPid during the 2nd quarter valued at about $56,000. AXQ Capital LP purchased a new stake in PolyPid in the second quarter worth about $87,000. Renaissance Technologies LLC bought a new position in shares of PolyPid during the first quarter valued at approximately $81,000. B. Riley Wealth Advisors Inc. lifted its holdings in shares of PolyPid by 32.7% during the third quarter. B. Riley Wealth Advisors Inc. now owns 20,085 shares of the company’s stock valued at $106,000 after purchasing an additional 4,955 shares during the last quarter. Finally, Connective Capital Management LLC purchased a new position in shares of PolyPid during the second quarter valued at approximately $343,000. Hedge funds and other institutional investors own 26.47% of the company’s stock.
About PolyPid
PolyPid Ltd. is an Israeli clinical-stage biopharmaceutical company developing products designed to deliver medicines locally and over an extended period. Its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology is intended to control the release of drugs at the site where they are administered. The company’s lead product candidate, D-PLEX100, uses the antibiotic doxycycline and is designed to be applied during surgery to provide sustained local drug delivery for the prevention of surgical-site infections.
See Also
- Five stocks we like better than PolyPid
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.
